Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.
A Clinical Study on the Safety and Effectiveness of CD19/CD22 Chimeric Antigen Receptor T Cells in the Treatment of Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.
Acute Lymphoblastic Leukemia
DRUG: PRG2302
Safe dose of PRG-2302 infusion, To evaluate the safe dose of PRG-2302 infusion, 3 dosage group were designed in this trial, they are 0.5×10\^6 CAR-T,1.0×10\^6 CAR-T, and 2.0×10\^6 CAR-T, Up to 24 months after PRG-2302 infusion|Occurrence of AE after PRG-2302 infusion, To evaluate the occurrence of AE after PRG-2302 infusion based on CTCAE v5.0, Up to 24 months after PRG-2302 infusion
A Clinical Study on the Safety and Effectiveness of CD19/CD22 Chimeric Antigen Receptor T Cells in the Treatment of Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.